


The power of partnership: the GAVI Alliance Board



GAVI's mission


To save children's lives and protect people's health by increasing access to immunisation in poor countries

Strategic goals 2011–2015

- **Accelerate the uptake and use of underused and new vaccines**
- **Contribute to strengthening the capacity of integrated health systems to deliver immunisation**
- **Increase the predictability of global financing and improve the sustainability of national financing for immunisation**
- **Shape vaccine markets**

What countries have achieved with GAVI support 2000 - 2011

- Immunised 326 million children
- Prevented over 5.5 million future deaths
- Accelerated vaccine introductions in over 70 countries
- Strengthened health systems to deliver immunisation
- Helped shape the market for vaccines



Source: These estimates and projections are produced by the WHO Department of Immunization, Vaccines and Biologicals, based on the most up-to-date data and models available as of 30 September 2011.


*Includes deaths averted by GAVI-supported vitamin A supplementation programmes.

Vaccine support

- **Currently supported:** pentavalent, pneumococcal, rotavirus, meningitis A, yellow fever and measles (second dose) vaccines, **human papillomavirus (HPV)**, rubella
- Also: meningitis and yellow fever vaccine stockpiles
- **Prioritised for future support:** Japanese encephalitis and typhoid vaccines
- **Monitoring development:** malaria, dengue

Opening the new HPV window: global burden of cervical cancer


- Estimated 530,000 new cases of cervical cancer in 2008
- 275,000 deaths in 2008, most of which in developing world



Source: Globocan 2008, International Agency for Research on Cancer.
Courtesy of Progress in Cervical Cancer Prevention:
The CCA Report Card, August 2011

Cervical cancer trends


Estimated number of cervical cancer deaths are increasing, especially in developing countries



Source: GLOBOCAN 2008, International Agency for Research on Cancer. Courtesy of PATH.


Why GAVI opened a HPV funding window: Status of vaccine introduction worldwide

Status as of July 2011




Source: Courtesy of Progress in Cervical Cancer Prevention:
The CCA Report Card, August 2011

GAVI eligible countries and experience with HPV vaccine



Source: Courtesy of PATH – preliminary assessment of country readiness

Two Pathways for HPV vaccine intro



National introduction of HPV vaccines

Application requirements:

- Identify a single year target vaccination cohort within 9-13 year old girls
- Demonstrated ability to deliver multi-dose vaccines to at least 50% of target vaccination cohort in an average size district
- Costing analysis of the proposed delivery strategy and evidence of non-GAVI resources to support delivery
- Where available, national strategy or roadmap for comprehensive cervical cancer prevention and control

HPV demonstration programme engages new partners



Photo: © UNICEF/NYHQ2011-0733/Asselin

- Engagement with new partners aims to integrate HPV vaccination and strengthen adolescent health and cervical cancer control
- Wide consultation with adolescent and reproductive health, cancer, education, academic and research partners, donor agencies in HPV programme design

Wide consultation with partners



HPV demonstration programme objectives

- **‘Learn by doing’** - support countries to assess potential of successful HPV vaccine delivery strategies to generate evidence for decision-making on national introduction
- **Integrated delivery of adolescent health interventions** - assess feasibility of integrating selected adolescent health interventions with HPV vaccine delivery
- **Comprehensive cervical cancer prevention** - encourage integration of primary prevention through HPV vaccination in national cervical cancer prevention and control strategy
- **How** – establish multi-disciplinary technical advisory group or through existing Inter-Agency Coordinating Committee

New Vaccines Support: timeline for next steps

Key dates in 2012	
31 August midnight	Deadline for submission of applications. Guidelines sent to governments. Available at http://www.gavialliance.org/support/apply/
Mid October	Independent Review Committee meeting > Countries will receive information letters with updates on the IRC recommendations
Early December	GAVI Board meet to consider and decide on IRC recommendations > Countries will receive decision letters to confirm doses, co-financing, introduction grant or operational support
HPV demonstration programmes	
31 October	Deadline for submission of applications for HPV demonstration programmes
Late November	GAVI HPV IRC meeting > Countries will receive notification of the outcome end of December

Thank you



GAVI/2011/Ed Harris



www.gavialliance.org

Background – Vaccine Investment Strategy

- **June:** Board agrees to use 'reduced overall disease burden' as portfolio objective



- **November:** Board recognizes need for comprehensive vaccine investment strategy

- **October:** Board endorses the portfolio: HPV, Japanese encephalitis, rubella and typhoid

- **November,** GAVI Board opened funding window for HPV country proposals provided:
 - Acceptable price for vaccine
 - Countries have 'demonstrated ability' to deliver vaccine
- Board also requested to develop HPV demonstration projects